Excess medicaid payments and the stock prices of drug companies.
作者信息
Grant William C
出版信息
J Manag Care Pharm. 2012 Oct;18(8):650. doi: 10.18553/jmcp.2012.18.8.650.
Abstract
摘要
相似文献
1
Excess medicaid payments and the stock prices of drug companies.医疗补助的超额支付与制药公司的股价。
J Manag Care Pharm. 2012 Oct;18(8):650. doi: 10.18553/jmcp.2012.18.8.650.
2
Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.因涉嫌对通用型劳拉西泮进行价格操纵而产生的长期医疗补助超额支付。
J Manag Care Pharm. 2012 Sep;18(7):506-15. doi: 10.18553/jmcp.2012.18.7.506.
3
Brand-name versus generic.品牌药与非专利药。
Health Aff (Millwood). 2007 Jul-Aug;26(4):1198-9; author reply 1199. doi: 10.1377/hlthaff.26.4.1198-a.
4
Pharmaceuticals and Medical Devices: Business Practices.药品和医疗器械：商业行为。
Issue Brief Health Policy Track Serv. 2016 Dec 27;2016:1-38.
5
High-cost generic drugs--implications for patients and policymakers.高价仿制药——对患者和政策制定者的影响。
N Engl J Med. 2014 Nov 13;371(20):1859-62. doi: 10.1056/NEJMp1408376.
6
Who's really raising drug prices?究竟是谁在真正抬高药价？
Time. 1999 Mar 8;153(9):46-8.
7
Enforcement actions involving Medicaid fraud and abuse, 1996-2009.1996 - 2009年涉及医疗补助欺诈与滥用的执法行动
Arch Intern Med. 2011 Apr 25;171(8):785-7. doi: 10.1001/archinternmed.2011.142.
8
Settlement plan approved for lorazepam, clorazepate overcharges.氯硝西泮和氯氮䓬多收费用的和解计划获批。
Am J Health Syst Pharm. 2001 Jun 15;58(12):1093. doi: 10.1093/ajhp/58.12.1093.
9
AWP reimbursement scrutinized by several states.多个州对平均批发价报销情况进行审查。
Manag Care. 2003 Apr;12(4):11-2.
10
Serious fraud office swoops on drug companies.严重欺诈办公室突袭制药公司。
BMJ. 2002 Apr 20;324(7343):935. doi: 10.1136/bmj.324.7343.935/a.
引用本文的文献
1
Off-Label Use vs Off-Label Marketing: Part 2: Off-Label Marketing-Consequences for Patients, Clinicians, and Researchers.药品未按批准用途使用与药品未按批准用途营销：第2部分：药品未按批准用途营销对患者、临床医生和研究人员的影响
JACC Basic Transl Sci. 2023 Mar 27;8(3):359-370. doi: 10.1016/j.jacbts.2022.12.012. eCollection 2023 Mar.
Zotero 插件